Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

PRIMARY OBJECTIVES:

I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved,
of risk-reducing salpingo-oophorectomy (RRSO) versus ovarian cancer screening (OCS) for
women at elevated genetic risk of ovarian cancer over a five-year period, using data from
GOG-0199 to model survival.

SECONDARY OBJECTIVES:

I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved,
of RRSO versus OCS for women at elevated genetic risk of ovarian cancer over a lifetime,
using stage-specific cohorts and population-based data to model long-term survival.
(Exploratory) II. To use value of information (VOI) methodology to set future research
priorities aimed at developing evidence-based approaches to the management of women who are
at elevated genetic risk of ovarian cancer. (Exploratory)

OUTLINE:

Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and
peritoneal cancers; number and timing of screening and serum tests performed; number and
timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and
overall survival (if available); and the incidence, type, and grade of significant adverse
events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed.
Cost of each medical intervention is also estimated.

Inclusion Criteria:

- Women who were eligible and evaluable for GOG-0199, a prospective, non-randomized,
natural history study

- Data collected from GOG-0199 available